NFE2L2 and ovarian serous tumor: Therapeutic targeting of NRF2 may represent a promising intervention point for serous ovarian tumor therapy; however, an improved understanding of the biological role of NRF2 in the context of ovarian tumor and nonmalignant (i.e., normal) cells must first be achieved, especially considering the importance of this pathway to normal ovarian function.